Omar Boraie who is an Urban New Brunswick, New Jersey developer has a Chair in Genomics Science at the Rutgers Cancer Institute of New Jersey. He has pledged $1.5 million and an anonymous donor will match the amount making the 18 chairs worth $3 million each. The funds will support the research of Precision Medicine and Genomic Research for treating and curing cancer. He wants people to be inspired to pledge for the 18 Chair Challenge and they can remain anonymous. View his profile on crunchbase.
Precision Medicine can place cancers in subcategories that have the similar characteristics and use the genetics of the patients for better results from treatments. This is a new approach to diagnosing, treating and eradicating the cancerous tumors. The diagnosis will include the genetics testing for a customized www.cinj.org/research/research-overview treatment for the patient. The Genome Sequencing is for patients that have limited treatment options, rare cancers, or have been diagnosed that the prescribed cancer treatment didn’t work.
The Rutgers University Cancer Institute has scientists who are physicians that have recognized that cancer is composed of many diseases with distinctive attributes. The Cancer will be classified by the Genomic Analysis instead of the location where the cancer is found. The physicians can classify the changes in the different types of cancer. This is an added guide for the physicians to customize a treatment plan that will benefit the patients.
According to Sam Boraie, son of Omar, the Rutgers Cancer Institute was one of the first facilities in the country and the only one in the state to apply Genomic sequencing as a precision medicine approach to patient care. The publications of News Wise are an integral part of the media for informing the public on what, why and where new breakthroughs are happening in the world.
The Genome Research and applying the Precision Medicine to the patient will give the patient more than a fighting chance to beat the disease. The funding from the 18 Chair Challenge will pave the way for more in-depth study of cancer biology, the changes within the cancer cells, and design more clinical trials.